Rhumbline Advisers Increases Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Rhumbline Advisers grew its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 6.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 192,281 shares of the company’s stock after purchasing an additional 11,317 shares during the quarter. Rhumbline Advisers owned approximately 0.12% of Xeris Biopharma worth $1,056,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC grew its stake in Xeris Biopharma by 31.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company’s stock worth $55,000 after buying an additional 3,847 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in shares of Xeris Biopharma by 446.0% in the fourth quarter. Mackenzie Financial Corp now owns 129,952 shares of the company’s stock valued at $441,000 after acquiring an additional 106,153 shares during the period. Squarepoint Ops LLC grew its position in shares of Xeris Biopharma by 118.2% during the fourth quarter. Squarepoint Ops LLC now owns 40,769 shares of the company’s stock worth $138,000 after acquiring an additional 22,084 shares during the last quarter. Two Sigma Advisers LP purchased a new position in shares of Xeris Biopharma during the fourth quarter worth approximately $47,000. Finally, Stonepine Capital Management LLC acquired a new position in shares of Xeris Biopharma in the 4th quarter valued at $618,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on XERS. Piper Sandler reiterated a “neutral” rating and set a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Leerink Partners increased their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Friday, March 7th. Wall Street Zen lowered Xeris Biopharma from a “buy” rating to a “hold” rating in a report on Thursday, May 22nd. Oppenheimer boosted their price target on Xeris Biopharma from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Friday, May 9th. Finally, Craig Hallum upped their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Xeris Biopharma has a consensus rating of “Moderate Buy” and a consensus price target of $6.25.

Insider Buying and Selling

In related news, insider Kevin Mcculloch purchased 25,000 shares of the stock in a transaction dated Friday, June 13th. The shares were acquired at an average cost of $4.38 per share, with a total value of $109,500.00. Following the purchase, the insider now directly owns 1,708,585 shares in the company, valued at $7,483,602.30. This trade represents a 1.48% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.47% of the stock is currently owned by corporate insiders.

Xeris Biopharma Stock Up 0.9%

Shares of Xeris Biopharma stock opened at $4.58 on Friday. The firm has a market cap of $716.22 million, a price-to-earnings ratio of -15.27 and a beta of 0.71. Xeris Biopharma Holdings, Inc. has a 52-week low of $2.03 and a 52-week high of $6.07. The company’s 50-day simple moving average is $4.57 and its 200-day simple moving average is $4.15.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. The business had revenue of $57.80 million for the quarter, compared to analyst estimates of $57.61 million. Equities research analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.